References
- Lloyd-Jones D, Adams R, Carnethon M, de Simone G, Ferguson TB, Flegal K, .; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics – 2009 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;119: e1–e161.
- Mancia G, de Backer G, Cifkova R, Dominiczak A, Fagard R, Germano G, . Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH). J Hypertens. 2007;25:1105–1187.
- Ezzati M, Lopez AD, Rodgers A, Vandeer Horn S, Murray CJL, the Comparative Risk Assessment Collaborative Group. Lancet. 2002;360:1347–1360.
- Coyne KS, Davis D, Frech F, Hill MN. Health-related quality of life in patients treated for hypertension: A review of the literature from 1990 to 2000. Clin Ther. 2002;24:142–169.
- Bramlage P, Thoenes M, Kirch W, Lenfant C. Clinical practice and recent recommendations in hypertension management-reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin. 2007;23: 783–791.
- Opie LH. Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther. 1988;2:177–189.
- Fogari R. Ankle oedema and sympathetic activation. Drugs. 2005;65 Suppl 2:21–7.
- Coca Payeras A, Sladek K, Lembo G, Alberici M. Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. Clin Drug Investig. 2007;27:623–632.
- Martinez-Martin F, Rodriguez-Rosas H, Peiro-Martinez I . Relationship between sympathetic activation, pulse pressure and heart rate in hypertensive type 2 diabetic patients with microalbuminuria, treated with manidipine vs. amlodipine. J Hypertens. 2005;23:376.
- Martinez-Martin F. Manidipine in hypertensive patients with metabolic syndrome: The MARIMBA Study. Expert Rev Cardiovasc Ther. 2009;7:863–867
- Zanchetti A, Omboni S, La Commare P, De Cesaris R, Palatini P. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol. 2001;38:642–650.
- Cohen J. Statistical power analysis for the behavioral sciences. 2nd. Hillsdale, NJ: Erlbaum; 1988.
- Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–1129.
- Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis, Version 2. Englewood Cliffs, NJ: Biostat Inc.; 2005.
- Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience. Med J Aust. 2008;188:224–227.
- Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. BMJ. 1995:311:293–295.
- Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23:2101–2107.
- Fogari R, Zoppi A, Corradi L, Preti P, Malalamani GD, Mugellini A. Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. J Hypertens. 2000;18:1871–1875.
- Fogari R, Malamani GD, Zoppi A, Mugellini A, Viscardi A, Lastoria C, . Manidipine has less oedematigeneous potential than amlodipine [abstract]. J Hypertens. 2000;18 Suppl 2:S154–155.